Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2009
11/26/2009WO2009141782A1 Tetrahydroisoquinolines as antimalarial agents
11/26/2009WO2009141738A2 Modified drugs for use in liposomal nanoparticles
11/26/2009WO2009141736A2 Inhibition of emmprin to treat multiple sclerosis
11/26/2009WO2009141718A2 Process for the preparation of prostaglandin analogues and intermediates thereof
11/26/2009WO2009141694A1 Endipalene formulations in the treatment of psoriasis
11/26/2009WO2009141645A1 Cancer therapy
11/26/2009WO2009141627A1 Treating niemann-pick disease type c and related disorders by elevating intracellular calcium
11/26/2009WO2009141575A1 Inhibitors of plk
11/26/2009WO2009141573A1 Novel polymorph of tegaserod adipate
11/26/2009WO2009141572A1 Novel polymorph
11/26/2009WO2009141571A1 Novel polymorph of tegaserod hydrochloride
11/26/2009WO2009141544A2 Use of a berry extract, especially a wolfberry extract, for treating dryness of keratin materials
11/26/2009WO2009141542A2 Use of a berry extract, especially a wolfberry extract, for maintaining and/or restoring the tonus and/or firmness of the skin
11/26/2009WO2009141541A2 Novel compositions which inhibit melanogenesis and uses thereof
11/26/2009WO2009141533A2 Pyrrole derivatives, preparation of same and therapeutic application thereof
11/26/2009WO2009141532A2 Pyrrole derivatives, preparation of same and therapeutic application thereof
11/26/2009WO2009141478A1 Thermoplastic paste for repairing living tissues
11/26/2009WO2009141450A2 Liposomes for drug delivery and methods for preparation thereof
11/26/2009WO2009141412A1 1,6-disubstituted 3-azabicyclo [3.1.0] hexane derivatives for use as triple reuptake inhibitors
11/26/2009WO2009141406A1 Maintenance therapy regimen for treating acne
11/26/2009WO2009141399A1 Tricyclic nitrogen containing compounds and their use as antibacterials
11/26/2009WO2009141398A1 Tricyclic nitrogen containing compounds and their use as antibacterials
11/26/2009WO2009141386A1 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
11/26/2009WO2009141329A1 Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier
11/26/2009WO2009141321A2 Tablettable chewing gums
11/26/2009WO2009141309A1 Delivery system for paliperidone
11/26/2009WO2009141249A1 Use of nucleotide furanoses as an agent for inhibiting furanosyl transferases
11/26/2009WO2009141238A1 Gpr119 receptor agonists
11/26/2009WO2009141167A1 Bosentan salts
11/26/2009WO2009141159A1 2,5-disubstituted imidazo[4,5-c]pyridines for treating muscular dystrophy
11/26/2009WO2009141146A1 5' triphosphate oligonucleotide with blunt end and uses thereof
11/26/2009WO2009141144A1 Co-crystals of duloxetine and cox-inhibitors for the treatment of pain
11/26/2009WO2009141142A1 Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion
11/26/2009WO2009141116A1 Fosphenytoin composition
11/26/2009WO2009141091A1 Novel [f-18] -labelled l-glutamic acid- and l-glutamine derivatives (i), use thereof and method for their production
11/26/2009WO2009141090A1 {f-19} -labeled l-glutamic acid and l-glutamine derivative (iii), use thereof and method for obtaining them
11/26/2009WO2009141079A1 Novel [f-18]-labelled l-glutamic acid and l-glutamine derivatives (ii), use thereof and method for their production
11/26/2009WO2009141074A1 Gummy candies based on dietary fibre
11/26/2009WO2009140984A1 Anhydrous and hydrate forms of crystalline 2- ( (2s, 3r, 4e, 6e, 1oe, 12s) -13- (4-fluorophenoxy) -2,3, 12- (trihydroxytrideca-4, 6, 10-trien-8-ynyl) oxy) acetic acid
11/26/2009WO2009140972A2 Modulation of the vps10p-domain receptors for the treatment of cardiovascular disease
11/26/2009WO2009140928A1 Dihydroindolinone derivatives
11/26/2009WO2009140887A1 A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof
11/26/2009WO2009140886A1 A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof
11/26/2009WO2009140863A1 Compositions comprising quinazoline derivatives, preparation methods and uses thereof
11/26/2009WO2009140859A1 Use of l-stepholidine (l-spd) derivatives
11/26/2009WO2009140853A1 Combination therapy for the treatment of influenza
11/26/2009WO2009140814A1 A method for preparing extractive containing sequoyitol from nephrolepis family and application
11/26/2009WO2009140769A1 3, 4 - substituted piperidine derivatives as renin inhibitors
11/26/2009WO2009140765A1 Selective caspase inhibitors and uses thereof
11/26/2009WO2009140764A1 Colon cleansing method and kit
11/26/2009WO2009140749A2 Standardized extract and fraction from hancornia speciosa leaves and pharmaceutical composition thereof
11/26/2009WO2009126332A3 Method for treatment of amyotrophic lateral sclerosis using talampanel
11/26/2009WO2009123948A3 Compounds and compositions as itpkb inhibitors
11/26/2009WO2009122301A3 Rasagiline mesylate particles and process for the preparation thereof
11/26/2009WO2009121155A3 Flavone containing compositions for treating mao associated disorders
11/26/2009WO2009121018A3 Opioid-nornicotine codrugs for pain management
11/26/2009WO2009121015A3 Calcimimetic compound for use in the treatment of epithelial injury
11/26/2009WO2009118338A3 Use of a polyphenolic type compound for preventing or treating a polyglutamine expansion neurodegenerative disease
11/26/2009WO2009117036A3 Bioactive molecules from co-cultivation of microbes
11/26/2009WO2009116774A3 Composition for treatment or prevention of restenosis
11/26/2009WO2009116044A3 Guanine nucleotide derivatives for treating bacterial infections
11/26/2009WO2009115562A3 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
11/26/2009WO2009115547A8 Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators
11/26/2009WO2009114658A3 Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
11/26/2009WO2009114098A3 Methods of treating hyperacidic disorders
11/26/2009WO2009113810A3 Pharmaceutical composition, use thereof, and method for the treatment or prevention of allergic and autoimmune diseases
11/26/2009WO2009112462A3 Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators
11/26/2009WO2009111028A8 Aurora kinase inhibitors
11/26/2009WO2009105853A3 Pharmaceutical combi-preparation comprising nootropic agents
11/26/2009WO2009102570A3 Treatments for neuropathy
11/26/2009WO2009102443A3 Octanoic acid formulations and methods of treatment using the same
11/26/2009WO2009102179A3 Apoptosis inducer composition for hormone-sensitive prostatic cancer cells
11/26/2009WO2009101199A3 Treatment of acne vulgaris; rosacea and rhinophym
11/26/2009WO2009100886A3 Formulations of flibanserin
11/26/2009WO2009093007A3 Immune modulation by regioselectively modified glycosides
11/26/2009WO2009087663A3 Oral controlled release coated tablet
11/26/2009WO2009087354A3 Skincare treatment
11/26/2009WO2009087091A3 Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy
11/26/2009WO2009085277A3 Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
11/26/2009WO2009083612A3 Flavonoid as means for the prophylaxis and treatment of neurodegenerative and other protein folding-aberration diseases
11/26/2009WO2009083211A3 Pharmaceutical compound for the prophylaxis and/or symptomatic treatment of cystic fibrosis
11/26/2009WO2009080722A3 Carboxylic derivatives for use in the treatment of cancer
11/26/2009WO2009079679A3 Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
11/26/2009WO2009076236A3 Micronized opioid compositions, formulations and dosage forms and methods of making same
11/26/2009WO2009074792A3 Substituted benzoquinones and hydroquinones in the treatment of periodontal diseases
11/26/2009WO2009074253A3 Clofarabine dietherphospholipid derivatives
11/26/2009WO2009073618A3 Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
11/26/2009WO2009071959A3 Composition containing itraconazole
11/26/2009WO2009066182A4 Method of treating cancer
11/26/2009WO2009058585A3 Non-aqueous water-miscible materials as vehicles for drug delivery
11/26/2009WO2009050506A3 Combination 059
11/26/2009WO2009047565A3 Zibotentan composition containing mannitol and/or microcrystalline cellulose
11/26/2009WO2009042402A3 Composition and method for treating rosacea
11/26/2009WO2009039460A3 Co-administration of pimavanserin with other agents
11/26/2009WO2009035542A3 Guanidine-containing compounds useful as muscarinic receptor antagonists
11/26/2009WO2009026430A3 Liposome formulations of boronic acid compounds
11/26/2009WO2009007677A3 Dsb repair- inhibitors as anti-tumour agents
11/26/2009WO2009006095A3 Dual portion lozenge dosage form
11/26/2009WO2009004038A3 Pirenzepine and derivatives thereof as anti-amyloid agents
11/26/2009WO2008150477A3 N-acetyl mannosamine as a therapeutic agent
1 ... 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 ... 7860